Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Hepatoma Research

• Publication date

  2017-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.20517/2394-5079.2017.28
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

  2017cited by this paper
• Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

  2016cited by this paper
• Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

  2016cited by this paper
• Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

  2016cited by this paper
• Natural killer cells in hepatitis C: Current progress.

  2016cited by this paper
• Hepatocellular carcinoma: a review

  2016cited by this paper
• Reversion of disease manifestations after HCV eradication.

  2016cited by this paper
• Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.

  2015cited by this paper
• Impact of natural killer cells on chronic hepatitis C and hepatocellular carcinoma

  2015cited by this paper
• Natural history of hepatitis C.

  2014cited by this paper
• Evolving epidemiology of hepatitis C virus.

  2011cited by this paper
• Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.

  2011cited by this paper
• A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.

  2010cited by this paper
• Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

  2010cited by this paper
• New therapies for hepatitis C virus infection.

  2009cited by this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cited by this paper
• Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.

  2005cited by this paper
• Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.

  2004cited by this paper
• Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

  1997cited by this paper
• Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

  1997influential reference

• Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

  2023cites this paper
• New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin

  2021cites this paper
• Predictive value &changes in Child-Pugh score in chronic hepatitis C cirrhotic patients treated with Direct Acting Antiviral agents

  2020cites this paper
• Cost-Effectiveness of HCV Core Antigen versus PCR for Monitoring Treatment Response in DAAS-Treated Egyptian Patients

  2020cites this paper
• Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed

  2020cites this paper
• Retrospective study of the outcome of liver transplantation in Egyptian patients with chronic hepatitis C virus infection

  2020cites this paper